Courtney Rice, EdM

Courtney Rice is a strategy consultant and insights leader with more than 20 years of experience guiding specialty therapies from development through commercialization. Her work focuses on genetic medicine and rare diseases, with a specialization in cell and gene therapy. She played a key role in the global commercial launch of the first systemic gene therapy approved for a rare disease and has since supported the development and global commercialization of 14+ CGT assets. Her experience spans payer strategy, brand development, and evidence generation, with a focus on aligning commercial approaches across payers, providers, and health systems. She has worked extensively at the intersection of payer and brand strategy to support coherent commercial decision-making. Courtney has deep experience with complex delivery and reimbursement models, including practice economics, buy-and-bill, group purchasing organizations, centers of excellence, diagnosis-related groups, and integrated delivery networks. Her biotech career spans Wall Street and Madison Avenue, including leadership roles at boutique life sciences strategy firms, market research organizations, and Madison Avenue healthcare advertising agencies. Courtney began her career at Putnam Investments, where she built a foundation in biotech financing and capital markets. She holds a Master’s degree in Organizational Behavior and Development from Harvard University and a Bachelor’s degree from the University of Massachusetts Amherst. She is a graduate of the Global Market Access Academy at the London School of Economics and is currently completing a Master of Science in Health Economics at the London School of Economics. Her international work includes consulting for Médecins Sans Frontières on HIV antiretroviral sourcing and access strategies in Cape Town, South Africa. Courtney has served as an adjunct lecturer at the University of New England and currently sits on the Board of GordonMD Global Investments. She also serves on the Commercialization Advisory Board of ISI Life Sciences Inc., a pre-IND oncology company, and Editpep, a gene-editing company focused on rare diseases that was incubated in the lab of 2020 Nobel Prize winner Jennifer Doudna.